ICOTF News and Press, Ico Therapeutics Inc

Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...

Satellos Bioscience Inc Ordinary Shares (ICOTF) is expected to report for Q3 2023

Satellos Bioscience press release ( OTC:ICOTF ): Q2 GAAP EPS of -C$0.07. Cash and cash equivalents of C$1.93M For further details see: Satellos Bioscience GAAP EPS of -C$0.07

Satellos Bioscience press release (OTC:ICOTF): Q1 GAAP EPS of -C$0.06. Cash and cash equivalents of C$2,775,494 as at March 31, 2022. For further details see: Satellos Bioscience GAAP EPS of -C$0.06

iCo Therapeutics  press release (OTC:ICOTF): FY GAAP EPS of -$0.64. Satellos had cash and cash equivalents of $4.87M as at December 31, 2021. For further details see: iCo Therapeutics GAAP EPS of -$0.64

iCo Therapeutics ([[ICOTF]] +25.8%) announces that its wholly owned subsidiary, Amphotericin B Technologies, has entered into an agreement with IIT Research Institute to test the in vivo efficacy of the company's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2 in the ...

Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in ...

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2021) - iCo Therapeutics Inc . (TSXV: ICO) (OTCQB: ICOTF) (" iCo " or the " Company "), announces that between February 1, 2021 and March 12, 2021, 20,280,000 warrants of the Company were exercised for common shares in the capital o...

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2021) - iCo Therapeutics Inc . (TSXV: ICO) (OTCQB: ICOTF) (" iCo " or the " Company "). At the request of IIROC, iCo Therapeutics Inc. (the "Company") wishes to confirm that the Company's management is unaware of any material chang...

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc . (TSXV: ICO) (OTCQB: ICOTF) (" iCo " or the " Company "), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted com...